Sudeep Pharma Ltd (SUDEEPPHRM) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Sudeep Pharma Ltd on NSE and BSE, with an AI summary of each filing.
Submission of Transcript for the Earnings call held on 29.10.2026
Transcript · 03 Nov 2026, 8:35 pm
Submission of Audio Recording of the Earnings call held on 29th October 2026
Audio / Video · 29 Oct 2026, 11:50 pm
Sudeep Pharma Releases Audio Recording for Earnings Call Held on 29th Oct'26 Sudeep Pharma Limited has made available the audio recording of its earnings conference call conducted on 29th Oct'26, pursuant to Regulation 30 of SEBI Listing Regulations. The recording has been uploaded to the company's official website following prior intimations regarding the call and the investor presentation. Sudeep Pharma confirmed that the written transcript of the earnings call will be submitted separately to the stock exchanges.
Submission of Investors Presentation
Investor Presentation · 29 Oct 2026, 1:36 am
Sudeep Pharma Q2FY27 Results and Expansion Updates Sudeep Pharma reported a record Q2FY27 performance, with consolidated revenue rising 21% YoY to Rs 196.7 crore and EBITDA growing 32% YoY to Rs 73.2 crore (margin at 37.2%, up ~70 bps). PAT rose 11% YoY to Rs 51.8 crore. For H1FY27, revenue reached Rs 355.0 crore (+23% YoY) with PAT at Rs 92.4 crore (+18% YoY). Key growth catalysts include USFDA approval for the 51,200 MT Nandesari facility and the upcoming Phase-1 25,000 MTPA battery-grade iron phosphate Dahej project targeted for completion by Mar'27.
Outcome of Board Meeting
Outcome · 28 Oct 2026, 10:51 pm
Submission of Unaudited Financials Results for the Quarter and half year ended 30th September 2026
Financial Result · 28 Oct 2026, 10:33 pm
Submission of Outcome of Board Meeting
Outcome · 28 Oct 2026, 10:17 pm
Sudeep Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakhs) ■ Revenue: 19,670 (+20.9% YoY | +24.3% QoQ) ■ EBITDA: 7,324 (+32.1% YoY | +33.4% QoQ) ■ EBITDA Margin (%): 37.2 (+314 bps YoY | +254 bps QoQ) ■ PAT: 5,145 (+12.5% YoY | +26.9% QoQ) ■ EPS (INR): 4.59 (+9.3% YoY | +27.9% QoQ) Sudeep Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Lakhs) Segmental Performance Pharmaceutical, food and nutrition ■ Revenue: 14,250 (+57.5% YoY | +31.4% QoQ) ■ EBIT: 5,512 (+99.2% YoY | +37.7% QoQ) ■ EBIT Margin (%): 38.7 (+811 bps YoY | +176 bps QoQ) Speciality ingredients ■ Revenue: 5,420 (-24.9% YoY | +8.7% QoQ) ■ EBIT: 1,274 (-46.9% YoY | +17.0% QoQ) ■ EBIT Margin (%): 23.5 (-973 bps YoY | +167 bps QoQ)
Press Release - FDA Approval for the new pharma greenfield manufacturing facility at 179 Nandesari, Gujarat.
Press Release · 26 Oct 2026, 6:01 pm
Sudeep Pharma Secures FDA Approval for 51,200 MT Greenfield Facility Sudeep Pharma Limited received Gujarat FDA approval on 26th Oct'26 to commence operations at its new greenfield facility at 179 Nandesari, Gujarat. The facility adds an annual installed capacity of 51,200 MT, targeting Pharma, Food & Nutrition, and Specialty Ingredients. Around 60% of capacity is allocated to existing product lines, while the remaining 40% will cater to newer, high-value molecules like bisglycinates, phosphates, and gluconates. Following customer qualifications, commercial supplies are slated to commence in H2 FY27.
Intimation for the Investor Meet Scheduled to be held on 29th October 2026 at 12:00 noon.
Intimation · 29 Oct 2026, 12:00 pm
Sudeep Pharma Schedules Q2 and H1FY27 Earnings Call on 29th Oct'26 Sudeep Pharma Limited will host an earnings conference call for analysts and investors on 29th Oct'26 at 12:00 PM IST to discuss its financial and operational performance for Q2 and H1FY27 (period ended 30th Sep'26). Organized by 360 ONE Capital Market Research, the call will feature senior management, including Managing Director Sujit Bhayani, Director Shanil Bhayani, and CFO Ketan Vyas. Access is available via universal dial-in numbers (+91 22 6280 1222 / +91 22 7115 8123) and international toll-free lines.
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Intimation · 28 Oct 2026, 5:30 am
SUDEEP PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 28-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 .
Intimation · 28 Oct 2026, 5:30 am
Sudeep Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2026 ,inter alia, to consider and approve the Un-audited Financial Results ....
Intimation · 28 Oct 2026, 5:30 am
Sudeep Pharma Board Meeting Scheduled on 28th Oct'26 for Q2 Financials Sudeep Pharma Limited has scheduled its Board of Directors meeting on 28th Oct'26 to consider, approve, and take on record the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. In accordance with SEBI insider trading regulations, the company's trading window for designated persons has been closed from 1st Oct'26 and will remain shut until 30th Oct'26 (both days inclusive), reopening 48 hours after the declaration of the financial results.
We wish to inform the changes in the SMP of the Company, arising due to completion of contractual arrangements between the company and Mr. Sendhil Pani, Managing Director of Sudeep Pharma ....
Change in Management · 05 Oct 2026, 10:28 pm
Sudeep Pharma Announces Senior Management Personnel Cessation at US Subsidiary Sudeep Pharma Limited has disclosed a change in its Senior Management Personnel following the completion of contractual arrangements with Mr. Sendhil Pani. Mr. Pani, who served as the Managing Director of the company's wholly owned subsidiary, Sudeep Pharma USA Inc., ceased to be designated as Senior Management Personnel effective 2nd Oct'26. Consequently, he is no longer associated with the company in this capacity under Regulation 16(1)(d) of SEBI Listing Regulations.
This is to inform that the officials of the Company will be attending the Investor Conference organized by Nuvama Emerging India CEO Forum 2026 on 28th September 2026 at 10:00 a.m. in Mumbai.
Intimation · 23 Sept 2026, 8:37 pm
Sudeep Pharma to Attend Nuvama Emerging India CEO Forum Sudeep Pharma Limited announced that company officials will attend the Nuvama Emerging India CEO Forum 2026 on 28th Sep'26 starting at 10:00 am in Mumbai. The interactions will involve 1x1 and group investor meetings. Discussions will be restricted to publicly available information, and no unpublished price-sensitive information will be shared.
Intimation on Cancellation of scheduled Investor /Analyst Meet
Intimation · 22 Sept 2026, 6:13 pm
Sudeep Pharma Cancels Scheduled Analyst and Investor Plant Visit Sudeep Pharma Limited has cancelled its scheduled Analyst and Investor Plant Visit, which was slated to take place on 23rd Sep'26 and 24th Sep'26 from 11:00 AM IST onwards. According to the company's regulatory filing under Regulation 30 of SEBI LODR Regulations, 2015, the cancellation is due to unforeseen exigencies.
we would like to inform that the officials of the Company has arranged a plant visit (Gujarat) for Investors/Analysts (Participants) on 23rd & 24th September 2026.
Intimation · 16 Sept 2026, 4:43 pm
Sudeep Pharma Schedules Investor Plant Visit in Gujarat Sudeep Pharma Limited has scheduled an analyst and institutional investor plant visit in Gujarat on 23rd and 24th Sep'26, starting from 11:00 AM onwards. The interaction will focus exclusively on publicly available information, and no unpublished price-sensitive information (UPSI) will be discussed during the sessions.
Submission of Earnings Call Transcript for the call held on 05.08.2026
Transcript · 11 Aug 2026, 9:38 pm
General Update
Others (Uncategorized) · 06 Aug 2026, 10:20 pm
Sudeep Pharma Corrects Annual General Meeting Attendee Count Sudeep Pharma Limited issued a correction on 06 Aug'26 regarding its recent Annual General Meeting filings. The company inadvertently reported 45 attendees in its AGM Outcome (04 Aug'26) and E-voting Results (05 Aug'26) submissions. The correct number of attendees was 44, comprising 5 from the promoter group and 39 from the public. This amendment clarifies a minor discrepancy in the company's regulatory disclosures. The previous filings should be updated to reflect the accurate attendance figure.
Submission of Audio Recording of Earnings Call held on 05.08.2026
Audio / Video · 05 Aug 2026, 10:30 pm
Sudeep Pharma Discloses Q1 FY27 Earnings Call Audio Recording Sudeep Pharma Limited has uploaded the audio recording of its earnings call, held on 5th Aug'26, to its corporate website. The call discussed the company's financial and operational performance for the first quarter of fiscal year 2027. A full transcript of the proceedings is expected to be submitted separately. This disclosure complies with SEBI's listing regulations. The company's equity is traded under the symbols SUDEEPPHRM on the NSE and 544619 on the BSE.
Submission of E-voting and Scrutinizer''s Report for the 37th Annual General Meeting held on 04.08.2026
Annual General Meeting · 05 Aug 2026, 6:07 pm
Submission of revised Investors Presentation
Investor Presentation · 05 Aug 2026, 3:04 am
Sudeep Pharma Q1FY27: Strong Growth Driven by Broad-Based Performance Sudeep Pharma reported strong Q1FY27 results with revenue at Rs. 158.3 Cr, up 27% YoY, and PAT at Rs. 40.6 Cr, up 30% YoY. Growth was broad-based across Pharma, Food & Nutrition, and Specialty Ingredients. EBITDA grew 25% YoY to Rs. 54.9 Cr, with a margin of 34.7%. Key strategic projects, including the Greenfield expansion and the Sudeep Advanced Materials (SAM) project for battery materials, remain on track, with the SAM project's Phase 1 commissioning planned for Mar'27.
Submission of Investors Presentation
Investor Presentation · 05 Aug 2026, 12:28 am
Sudeep Pharma Q1FY27: Strong Revenue Growth and Strategic Expansion Sudeep Pharma reported strong Q1FY27 results with revenue at Rs. 158.3 Cr, up 27% YoY. EBITDA grew 25% YoY to Rs. 54.9 Cr, with a margin of 34.7%. PAT increased 30% YoY to Rs. 40.6 Cr, yielding a PAT margin of 25.6%. Growth was broad-based across Pharma, Food & Nutrition, and Specialty Ingredients. Strategic initiatives are on track, including a Greenfield expansion and the Sudeep Advanced Materials (SAM) project for battery-grade iron phosphate, with Phase 1 commissioning planned for Mar'27. Exports comprised 55% of revenue.
Submission of Investors Presentation
Investor Presentation · 05 Aug 2026, 12:22 am
Sudeep Pharma Q1FY27: Strong Revenue and Profit Growth with Margin Expansion Sudeep Pharma reported strong Q1FY27 results with revenue at Rs. 158.3 Cr, up 27% YoY, driven by broad-based growth. EBITDA grew 25% YoY to Rs. 54.9 Cr, though the margin contracted slightly to 34.7% from 35.1%. Profit After Tax (PAT) increased 30% YoY to Rs. 40.6 Cr, with the PAT margin expanding to 25.6% from 25.0%. Key growth projects, including the Greenfield expansion and the Sudeep Advanced Materials (SAM) plant for battery materials, remain on track for commissioning by Mar'27. Exports comprised 55% of revenue.
Submission of Financials as on 30.06.2026
Financial Result · 04 Aug 2026, 11:42 pm
Sudeep Pharma Reports Strong Q1'27 Results with 30% YoY Revenue Growth Sudeep Pharma Limited reported strong Q1'27 results for the period ended 30 Jun'26, with consolidated revenue from operations at ₹15,827.05 lakhs, a 26.7% YoY increase. Net profit rose 29.8% YoY to ₹4,058.69 lakhs. The performance was driven by the Pharmaceutical, food and nutrition segment, which saw revenue grow 22.2% YoY to ₹10,841.37 lakhs. On a sequential basis, revenue declined 13.2% QoQ, and net profit fell 16.4% QoQ. The basic EPS for the quarter stood at ₹3.59.
Submission of Outcome of Board Meeting
Outcome · 04 Aug 2026, 11:32 pm
Sudeep Pharma Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakhs) ■ Revenue: 15,827 (+26.7% YoY | -13.2% QoQ) ■ EBITDA: 5,491 (+25.2% YoY | -12.3% QoQ) ■ EBITDA Margin (%): 34.7 (-43 bps YoY | +37 bps QoQ) ■ PAT: 4,055 (+31.6% YoY | -17.0% QoQ) ■ EPS (INR): 3.59 (+26.4% YoY | -18.0% QoQ) Sudeep Pharma Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakhs) Segmental Performance Pharmaceutical, food and nutrition ■ Revenue: 10,841 (+30.6% YoY | +20.3% QoQ) ■ EBITDA: 4,186 (+47.8% YoY | +42.4% QoQ) ■ EBITDA Margin (%): 38.6 (+448 bps YoY | +598 bps QoQ) Speciality ingredients ■ Revenue: 4,986 (+18.9% YoY | -45.9% QoQ) ■ EBITDA: 1,305 (-16.1% YoY | -60.7% QoQ) ■ EBITDA Margin (%): 26.2 (-1091 bps YoY | -981 bps QoQ)
Submission of proceedings of the 37th Annual General Meeting held on 4th August 2026
Annual General Meeting · 04 Aug 2026, 10:37 pm